Rachel Penn

ICH E6 (R3) is here, but only 19% of the industry is ready. While awareness is high, meaningful action is lagging.

TRI is proud to join the Veeva R&D Summit as a Product Partner, showcasing our collaboration.

Explore five common mistakes that can derail your clinical trial and how OPRA helps teams manage risk.

Discover how TRI is transforming clinical research through smarter, data-driven solutions.

RBQM is redefining how clinical trials are designed, enabling smarter, more resilient research.

Explore how sponsors and CROs must rethink collaboration and embed quality into every layer of trial execution.

Explore how E6 (R3) reshapes trial design, oversight, and culture, and why the industry must be ready to respond.

ICH E6 (R3) sets a new global benchmark for Good Clinical Practice, modernizing oversight with principle-based, risk-driven, and digitally enabled trial design.